August 14, 2020 -- IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome immune profiling platform will be used to study cellular drivers of durable and protective immune response to the virus.
IsoPlexis' T cell and other immune cell polyfunctional cytokine responses have been able to predict a variety of responses in human and mice studies throughout cancer immunology and infectious disease. Also, Moriya Tsuji, a professor of medicine at Columbia, has published vaccine studies of malaria and also in oncology that used IsoPlexis' single-cell functional proteomics platform.
Columbia and IsoPlexis plan to detect and discover critical components in the overall cellular response to COVID-19, which can then be used to create therapies.